Hyponatremia in cirrhosis: Results of a patient population survey

Hepatology

Volumn 44, Issue 6, 2006, Pages 1535-1542

  Angeli, Paolo ^a   Wong, Florence ^b,e   Watson, Hugh ^c   Ginès, Pere ^d   Castelpoggi, C H F ^e   Ferraz, M L ^e   Bain, V G ^e   Pomier Layrargues, G B ^e   Milutinovic, S ^e   Rumboldt, Z ^e   Bruha, R ^e   Hulek, P ^e   Lata, J ^e   Guyader, D ^e   Mallat, A ^e   Fleig, W ^e   Gerbes, A ^e   Ujszaszy L ^e   Angeli, P ^e   Pinzello, G ^e   Salerno, F ^e   Goh, K L ^e   Lim, S G ^e   Fock, K M ^e   Del Arbol, L Ruiz ^e   Diaz, F ^e   Gines P ^e   Guevara, M ^e   Renner, E ^e   Yang, S S ^e   Blei, A T ^e   Garcia Tsao, G ^e   more..

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF TORONTO   (Canada)

^c SANOFI   (France)

^d UNIVERSITY OF BARCELONA   (Spain)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; BUMETANIDE; CANRENOATE POTASSIUM; CHLOROTHIAZIDE; ETACRYNIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; METOLAZONE; SODIUM; SPIRONOLACTONE; TORASEMIDE;

ADULT; AGED; ARTICLE; ASCITES; BACTERIAL PERITONITIS; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH SURVEY; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HOSPITAL PATIENT; HUMAN; HYPONATREMIA; KIDNEY FUNCTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; SODIUM BLOOD LEVEL;

EID: 33845637697     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21412     Document Type: Article

References (32)

1. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956;271:1121-1125.
2. Shear L, Hall PW 3rd, Gabuzda GJ. Renal failure in patients with cirrhosis of the liver. II. Factors influencing maximal urinary flow rate. Am J Med 1965;39:199-209.
3. Arroyo V, Rodes J, Gutierrez-Lizarraga MA. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Dig Dis Sci 1976;21:249-256.
4. Ginès P, Berl T, Bernardi M, Bichet DG, Hamon G, Jimenez W, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. HEPATOLOGY 1998;8:851-864.
5. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982;96:423-427.
6. Epstein M. Derangements of renal water handling in liver disease. Gastroenterology 1985;89:1415-1425.
7. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J, et al. Peripheral arteriolar vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988;8:1151-1157.
8. Llach J, Ginès P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94:482-487.
9. Cosby RL, Yee B, Schrier RW. New classification with prognostic value in cirrhotic patients. Miner Electrolyte Metab 1989;15:261-266.
10. Fernandez-Esparrach G, Sanchez-Fueyo A, Ginès P, Uriz J, Quinto L, Ventura PJ, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001;34:46-52.
11. Heuman DM, Abou-assi SG, Habib A, Williams LM, Stravitz RT, Sanyal AJ, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at risk for early death. HEPATOLOGY 2004;40:802-810.
12. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. HEPATOLOGY 2005;41:32-39.
13. Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005;11:336-343.
14. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130:1652-1660.
15. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. HEPATOLOGY 1996;23:164-176.
16. Borroni G, Maggi A, Sangiovanni A, Cazzaniga M, Salerno F. Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Digest Liver Dis 2000;32:605-610.
17. Porcel A, Diaz F, Rendom P, Macias M, Martin-Herrera L, Giron-Gonzalez J. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002;162:323-328.
18. Arroyo V. Milestones in liver disease: Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure (Lancet 1956;2:1221-1225). J Hepatol 2002;36:315-320.
19. Bernardi M, Laffi G, Salvagnini M, Azzena G, Bonato S, Marra F, et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. Liver 1993;13:156-162.
20. Angeli P, Pria MD, De Bei E, Albino G, Caregaro L, Merkel C, et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. HEPATOLOGY 1994; 19:72-79.
21. Haussinger D, Laubenberger J, vom Dahl S, Ernst T, Bayer S, Langer M, et al. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypo-osmolarity and hepatic encephalopathy. Gastroenterology 1994;107:1475-1480.
22. Restuccia T, Gomez-Anson B, Guevara M, Alessandria C, Torre A, Alayrach ME, et al. Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. HEPATOLOGY 2004;39:1613-1622.
23. Häussinger D. Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. HEPATOLOGY 2006;43:1187-1190.
24. Cordoba J, Gottstein J, Blei AT. Chronic hyponatremia exacerbates ammonia-induced brain edema in rats after portacaval anastomosis. J Hepatol 1998;29:589-594.
25. Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. HEPATOLOGY 2004;39:464-470.
26. Ginès P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003;362:1819-1827.
27. Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. HEPATOLOGY 2005;41:1282-1289.
28. Gines A, Escorsell A, Ginès P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236.
29. Ruiz del Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal and hepatic haemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. HEPATOLOGY 2003;38:1210-1218.
30. Ruiz del Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. HEPATOLOGY 2005;42:439-447.
31. Angeli P, Guarda S, Fasolato S, Miola E, Craighero R, Del Piccolo F, et al. Switch therapy with ciprofloxacin vs intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 2006;23:75-84.
32. Terra C, Guevara M, Torre A, Gilabert R, Fernández J, Martín-Llahí M, et al. Renal failure in cirrosis and sepsis unrelated to spontaneous bacterial peritonitis. Value of MELD score. Gastroenterology 2006;129:1944-1953.